Abadjian G, Antoun R
Université Saint, Joseph-Hôtel-Dieu de France, Beyrouth.
J Med Liban. 1996;44(1):10-5.
The present study was performed on 45 mammary biopsies submitted to the Pathology Department, Hôtel-Dieu de France Hospital, for evaluation of hormonal receptor. Histological typing and grading did not reveal any difference with the literature, but the mean size of tumor at clinical presentation was 4 cm (+/- 1.6) and 83% of patients with known lymph node status, had metastases. Immunohistochemical assay for hormonal receptors on frozen sections disclosed positivity for estrogen and progesterone receptors in 18 cases (43%), similar to other studies. pS2, intracytoplasmic estrogen-induced protein, is positive in 19 out of 32 studied cases (59%), similar to what is reported by others. The latter does not appear to bring more information than hormone receptors considering therapy and prognosis. Oncoprotein C-erb B2 membrane over-expression is noted in 65% with no significant correlation to histological grade, size of tumor or node status. Antigen Ki-67 marker demonstrates high proliferation rates in 19 tumors (48.7%). The markers studied do not seem to be more conclusive than the hormone receptors. The major fact disclosed by the study of this small series is the advanced stage at clinical presentation, urging an adequate medical education of the Lebanese population, and prompting to appropriate self-screening. Nevertheless, new tumor markers are continuously presented in the literature. In this era of marker extravaganza, a "wait-and-see" attitude would be a wise alternative.
本研究对提交至法国迪厄医院病理科进行激素受体评估的45份乳腺活检样本进行。组织学分型和分级与文献报道无差异，但临床表现时肿瘤的平均大小为4厘米（±1.6），已知淋巴结状态的患者中83%有转移。对冰冻切片进行的激素受体免疫组化分析显示，18例（43%）雌激素和孕激素受体呈阳性，与其他研究相似。pS2，一种胞质内雌激素诱导蛋白，在32例研究病例中有19例（59%）呈阳性，与其他人的报道相似。考虑到治疗和预后，后者似乎并未比激素受体提供更多信息。癌蛋白C-erb B2膜过表达在65%的病例中被观察到，与组织学分级、肿瘤大小或淋巴结状态无显著相关性。抗原Ki-67标记物在19个肿瘤（48.7%）中显示出高增殖率。所研究的标记物似乎并不比激素受体更具决定性。对这个小系列研究揭示的主要事实是临床表现时处于晚期，这促使对黎巴嫩人群进行充分的医学教育，并促使进行适当的自我筛查。然而，文献中不断有新的肿瘤标记物出现。在这个标记物泛滥的时代，“观望”态度可能是明智的选择。
